All-cause hospitalisation among people living with HIV according to gender, mode of HIV acquisition, ethnicity, and geographical origin in Europe and North America: findings from the ART-CC cohort collaboration.


Journal

The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003

Informations de publication

Date de publication:
10 2023
Historique:
received: 30 01 2023
revised: 27 07 2023
accepted: 01 08 2023
medline: 23 10 2023
pubmed: 1 10 2023
entrez: 30 9 2023
Statut: ppublish

Résumé

Understanding demographic disparities in hospitalisation is crucial for the identification of vulnerable populations, interventions, and resource planning. Data were from the Antiretroviral Therapy Cohort Collaboration (ART-CC) on people living with HIV in Europe and North America, followed up between January, 2007 and December, 2020. We investigated differences in all-cause hospitalisation according to gender and mode of HIV acquisition, ethnicity, and combined geographical origin and ethnicity, in people living with HIV on modern combination antiretroviral therapy (cART). Analyses were performed separately for European and North American cohorts. Hospitalisation rates were assessed using negative binomial multilevel regression, adjusted for age, time since cART intitiaion, and calendar year. Among 23 594 people living with HIV in Europe and 9612 in North America, hospitalisation rates per 100 person-years were 16·2 (95% CI 16·0-16·4) and 13·1 (12·8-13·5). Compared with gay, bisexual, and other men who have sex with men, rates were higher for heterosexual men and women, and much higher for men and women who acquired HIV through injection drug use (adjusted incidence rate ratios ranged from 1·2 to 2·5 in Europe and from 1·2 to 3·3 in North America). In both regions, individuals with geographical origin other than the region of study generally had lower hospitalisation rates compared with those with geographical origin of the study country. In North America, Indigenous people and Black or African American individuals had higher rates than White individuals (adjusted incidence rate ratios 1·9 and 1·2), whereas Asian and Hispanic people living with HIV had somewhat lower rates. In Europe there was a lower rate in Asian individuals compared with White individuals. Substantial disparities exist in all-cause hospitalisation between demographic groups of people living with HIV in the current cART era in high-income settings, highlighting the need for targeted support. Royal Free Charity and the National Institute on Alcohol Abuse and Alcoholism.

Sections du résumé

BACKGROUND
Understanding demographic disparities in hospitalisation is crucial for the identification of vulnerable populations, interventions, and resource planning.
METHODS
Data were from the Antiretroviral Therapy Cohort Collaboration (ART-CC) on people living with HIV in Europe and North America, followed up between January, 2007 and December, 2020. We investigated differences in all-cause hospitalisation according to gender and mode of HIV acquisition, ethnicity, and combined geographical origin and ethnicity, in people living with HIV on modern combination antiretroviral therapy (cART). Analyses were performed separately for European and North American cohorts. Hospitalisation rates were assessed using negative binomial multilevel regression, adjusted for age, time since cART intitiaion, and calendar year.
FINDINGS
Among 23 594 people living with HIV in Europe and 9612 in North America, hospitalisation rates per 100 person-years were 16·2 (95% CI 16·0-16·4) and 13·1 (12·8-13·5). Compared with gay, bisexual, and other men who have sex with men, rates were higher for heterosexual men and women, and much higher for men and women who acquired HIV through injection drug use (adjusted incidence rate ratios ranged from 1·2 to 2·5 in Europe and from 1·2 to 3·3 in North America). In both regions, individuals with geographical origin other than the region of study generally had lower hospitalisation rates compared with those with geographical origin of the study country. In North America, Indigenous people and Black or African American individuals had higher rates than White individuals (adjusted incidence rate ratios 1·9 and 1·2), whereas Asian and Hispanic people living with HIV had somewhat lower rates. In Europe there was a lower rate in Asian individuals compared with White individuals.
INTERPRETATION
Substantial disparities exist in all-cause hospitalisation between demographic groups of people living with HIV in the current cART era in high-income settings, highlighting the need for targeted support.
FUNDING
Royal Free Charity and the National Institute on Alcohol Abuse and Alcoholism.

Identifiants

pubmed: 37777287
pii: S2468-2667(23)00178-0
doi: 10.1016/S2468-2667(23)00178-0
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e776-e787

Subventions

Organisme : NIAAA NIH HHS
ID : U01 AA026209
Pays : United States

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests SMR reports fellowship payments from the Royal Free Charity. FCL reports grants from the National Institute for Health and Care Research paid to their institution. JACS and SMI report grants from the National Institutes of Health paid to their institution. JACS also received grants from the UK National Institute for Health and Care Research paid to their institution. MvdV received grants and consulting fees from Gilead, ViiV, and MSD paid to their institution. GW reports grants from Gilead and Roche Diagnostics and honoraria from Gilead, ViiV, and MSD. MJG participated on advisory boards for Merck, Gilead, and ViiV. HMC and JC report separate grants from the National Institutes of Health paid to their institution. HMC received grants from ViiV and AHRQ paid to their institution. LW reports grants from ANRS MIE. All other authors declare no competing interests.

Auteurs

Sophia M Rein (SM)

CAUSALab and Department of Epidemiology, Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA; Institute for Global Health, UCL, London, UK. Electronic address: srein@hsph.harvard.edu.

Fiona C Lampe (FC)

Institute for Global Health, UCL, London, UK.

Suzanne M Ingle (SM)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Jonathan A C Sterne (JAC)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Bristol Biomedical Research Centre, Bristol, UK; Health Data Research UK South-West, Bristol, UK.

Adam Trickey (A)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

M John Gill (MJ)

Department of Medicine, University of Calgary, Calgary, AB, Canada.

Vasileios Papastamopoulos (V)

Department of Internal Medicine and Infectious Diseases, Evaggelismos General Hospital, Athens, Greece.

Linda Wittkop (L)

University of Bordeaux, INSERM, Bordeaux Population Health-U1219, CIC1401-EC, Bordeaux, France; CHU de Bordeaux-Bordeaux University Hospital, Service d'information médicale, INSERM, CIC-EC 1401, Bordeaux, Franc; SISTM, INRIA, University of Bordeaux, Talence, France.

Marc van der Valk (M)

Department of Infectious Diseases, Amsterdam Infection and Immunity Institute (AI&II), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Stichting HIV Monitoring, Amsterdam, Netherlands.

Maria Kitchen (M)

Department of Dermatology, Venereology, and Allergology, Medical University of Innsbruck, Innsbruck, Austria.

Jodie L Guest (JL)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.

Derek D Satre (DD)

Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.

Gilles Wandeler (G)

Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland.

Pepa Galindo (P)

Hospital Clínico Universitario de Valencia, Valencia, Spain.

Jessica Castilho (J)

Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Heidi M Crane (HM)

Department of Medicine and Department of Health Services, University of Washington, Seattle, WA, USA.

Colette J Smith (CJ)

Institute for Global Health, UCL, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH